Skip to main content
OncoTherapy Science, Inc. logo

OncoTherapy Science, Inc. — Investor Relations & Filings

Ticker · 4564 ISIN · JP3202150003 LEI · 529900CIAZCAIG781H52 T Professional, scientific and technical activities
Open in API
Filings indexed 71 across all filing types
Latest filing 2018-06-22 Annual Report
Country JP Japan
Listing T 4564

About OncoTherapy Science, Inc.

https://www.oncotherapy.co.jp/en/

OncoTherapy Science, Inc. is a biopharmaceutical company focused on the research and development of novel anti-cancer therapies. The company utilizes cancer-specific gene data and comprehensive cancer genome analysis to discover and develop molecular-targeted drugs, antibody drugs, cancer vaccines, and new immunotherapies. Its key technological focuses include liquid biopsy, neoantigen prediction, and T-cell receptor (TCR) repertoire analysis using next-generation sequencing. The company's primary objective is to develop highly effective cancer treatments with minimal adverse events and side effects for patients.

Recent filings

Filing Released Lang Actions
有価証券報告書－第17期(平成29年4月1日－平成30年3月31日)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which translates to 'Annual Securities Report'. It contains detailed financial statements, management indicators, company history, and business descriptions for the fiscal year ending March 31, 2018. This is the standard Japanese regulatory filing equivalent to a 10-K in the United States. FY 2018
2018-06-22 Japanese
四半期報告書－第17期第3四半期(2017/10/01－2017/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '第３四半期報告書' (Third Quarter Report) for OncoTherapy Science, Inc., covering the period from October 1, 2017, to December 31, 2017. It contains detailed financial statements, management analysis of business performance, and corporate information, which aligns with the definition of an Interim/Quarterly Report (IR). Q3 2017
2018-02-05 Japanese
四半期報告書－第17期第2四半期(2017/07/01－2017/09/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) filed with the Kanto Local Finance Bureau under the Financial Instruments and Exchange Act. It contains detailed financial statements, management analysis (MD&A), and business updates for the second quarter of the 17th fiscal period (April 1, 2017 to September 30, 2017). It is a comprehensive financial report for a period shorter than a full fiscal year, fitting the definition of an Interim/Quarterly Report (IR). Q2 2017
2017-11-06 Japanese
四半期報告書－第17期第1四半期(2017/04/01－2017/06/30)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (四半期報告書) for OncoTherapy Science, Inc., covering the period from April 1, 2017, to June 30, 2017. It contains detailed financial statements, management analysis, and regulatory disclosures required under the Financial Instruments and Exchange Act of Japan. As it is a comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report. Q1 2017
2017-08-07 Japanese
有価証券報告書－第16期(2016/04/01－2017/03/31)
Annual Report Classification · 100% confidence The document is a Japanese '有価証券報告書' (Yuuka Shouken Houkokusho), which translates to 'Annual Securities Report'. This is the standard, comprehensive annual financial filing required by the Financial Services Agency of Japan under the Financial Instruments and Exchange Act. It contains detailed financial statements, business descriptions, and management analysis for the fiscal year ending March 31, 2017. This corresponds to the 10-K filing type in the provided schema. FY 2017
2017-06-20 Japanese
四半期報告書－第16期第3四半期(2016/10/01－2016/12/31)
Interim / Quarterly Report Classification · 100% confidence The document is a '第３四半期報告書' (Third Quarter Report) for OncoTherapy Science, Inc., filed under the Financial Instruments and Exchange Act in Japan. It contains detailed financial statements, management analysis, and audit review information for the period ending December 31, 2016. As it is a comprehensive quarterly financial report containing actual financial data, it is classified as an Interim/Quarterly Report (IR). 9M 2017
2017-02-06 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.